Bristol-Myers Squibb (BMY) is listed in the 12 Best Stocks to Buy Now for Passive Income. The global biopharmaceutical company has a long history of drug innovation and strategic mergers, focusing on treatments in oncology, cardiovascular health, immunology, neuroscience, and blood disorders.

Bristol-Myers Squibb (BMY) has invested around $100 billion in acquisitions to offset revenue losses from expiring drug patents. The company remains a strong dividend player, declaring a quarterly dividend of $0.62 per share on September 17, with a 16-year track record of dividend growth and a dividend yield of 5.51% as of September 22.

While BMY is a solid investment, some AI stocks may offer higher potential returns with less downside risk. For insights on an undervalued AI stock that could benefit from current economic trends, check out the report on the best short-term AI stock.

For more investment ideas, explore the 12 Best Retail Dividend Stocks to Buy Now and 11 Cheap Quarterly Dividend Stocks to Buy Right Now. Stay informed and make informed investment decisions. No disclosures provided.

Read more at Yahoo Finance: Why Bristol-Myers Squibb (BMY) Deserves a Spot in Passive Income Portfolios